costunolide (Bio-Tech Pharmacal Inc)
86
Structured Review
Bio-Tech Pharmacal Inc
costunolide
Costunolide, supplied by Bio-Tech Pharmacal Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/costunolide/costunolide/pm41186629-69-0-6
Average 86 stars, based on 1 article reviews
Costunolide, supplied by Bio-Tech Pharmacal Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/costunolide/costunolide/pm41186629-69-0-6
Average 86 stars, based on 1 article reviews
costunolide - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
High Performance Liquid Chromatography:Article Title: Study on the mechanism of costunolide inhibiting triple-negative breast cancer by EGFR ubiquitination and degradation to suppress the ERK/AKT signaling pathway. Article Snippet: and human epidermal growth factor receptor 2 (HER2) expression, result in an inherent resistance to endocrine therapy and HER2-targeted drugs(Jitariu et al. 2017).. Compared to other molecular subtypes, the TNBC patient population is relatively younger, more prone to early metastasis, and has a higher risk of recurrence with poorer prognosis (Kwa and Adams 2018).. Although systemic chemotherapy remains the primary treatment approach, TNBC patients still face treatment resistance. Saline:Article Title: Study on the mechanism of costunolide inhibiting triple-negative breast cancer by EGFR ubiquitination and degradation to suppress the ERK/AKT signaling pathway. Article Snippet: and human epidermal growth factor receptor 2 (HER2) expression, result in an inherent resistance to endocrine therapy and HER2-targeted drugs(Jitariu et al. 2017).. Compared to other molecular subtypes, the TNBC patient population is relatively younger, more prone to early metastasis, and has a higher risk of recurrence with poorer prognosis (Kwa and Adams 2018).. Although systemic chemotherapy remains the primary treatment approach, TNBC patients still face treatment resistance. CCK-8 Assay:Article Title: Study on the mechanism of costunolide inhibiting triple-negative breast cancer by EGFR ubiquitination and degradation to suppress the ERK/AKT signaling pathway. Article Snippet: and human epidermal growth factor receptor 2 (HER2) expression, result in an inherent resistance to endocrine therapy and HER2-targeted drugs(Jitariu et al. 2017).. Compared to other molecular subtypes, the TNBC patient population is relatively younger, more prone to early metastasis, and has a higher risk of recurrence with poorer prognosis (Kwa and Adams 2018).. Although systemic chemotherapy remains the primary treatment approach, TNBC patients still face treatment resistance. Lysis:Article Title: Study on the mechanism of costunolide inhibiting triple-negative breast cancer by EGFR ubiquitination and degradation to suppress the ERK/AKT signaling pathway. Article Snippet: and human epidermal growth factor receptor 2 (HER2) expression, result in an inherent resistance to endocrine therapy and HER2-targeted drugs(Jitariu et al. 2017).. Compared to other molecular subtypes, the TNBC patient population is relatively younger, more prone to early metastasis, and has a higher risk of recurrence with poorer prognosis (Kwa and Adams 2018).. Although systemic chemotherapy remains the primary treatment approach, TNBC patients still face treatment resistance. Staining:Article Title: Study on the mechanism of costunolide inhibiting triple-negative breast cancer by EGFR ubiquitination and degradation to suppress the ERK/AKT signaling pathway. Article Snippet: and human epidermal growth factor receptor 2 (HER2) expression, result in an inherent resistance to endocrine therapy and HER2-targeted drugs(Jitariu et al. 2017).. Compared to other molecular subtypes, the TNBC patient population is relatively younger, more prone to early metastasis, and has a higher risk of recurrence with poorer prognosis (Kwa and Adams 2018).. Although systemic chemotherapy remains the primary treatment approach, TNBC patients still face treatment resistance. |